Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
Inventors
Weinschenk, Toni • FRITSCHE, Jens • Singh, Harpreet • MAHR, Andrea • OTT, Martina • Wagner, Claudia • Schoor, Oliver
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12295994-B2
Publication Date
2025-05-13
Expiration Date
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Core Innovation
The disclosed subject matter relates to isolated peptides defined by the amino acid sequence TLDGAAVNQV (SEQ ID NO: 22), provided in the form of a pharmaceutically acceptable salt or a salt. The peptides are framed as components suitable for pharmaceutical and immunotherapy-related contexts, including peptide compositions and peptide-containing vaccine compositions.
The disclosure further relates to tumor-associated T-cell peptide epitopes for pancreatic cancer immunotherapy, including peptide- or peptide-MHC-complex-based vaccine compositions. It also describes use of these epitopes to generate TCR-engineered cells or activated T cells for killing target cells, and to target antibodies or soluble TCRs, with HLA allele coverage concepts including HLA-A*02 binding class I peptides and elongated HLA class II-binding variants.
The document additionally describes a broader pancreatic cancer immunotherapy platform involving expression vector elements, host cells, antigen-presenting cells such as dendritic cells, HLA ligands and presentation, CD8+ T-cell priming concepts using artificial APCs, and analytical approaches for identifying tumor-associated peptides and characterizing MHC presentation. It also discusses peptide immunogenicity assessment in vitro, immunological binding reagents, biomarker concepts based on peptide over-presentation and underlying gene over-expression, and the use of adjuvants within immunotherapy compositions.
Claims Coverage
The independent claims cover the isolated peptide TLDGAAVNQV (SEQ ID NO: 22) in salt form, with two claim families differing by whether the salt is specified as pharmaceutically acceptable or generic. The claim set is centered on this single inventive feature, with dependent refinements addressing salt subtype, carrier-containing compositions, and optional adjuvants.
Isolated TLDGAAVNQV peptide as pharmaceutically acceptable salt
An isolated peptide consisting of the amino acid sequence TLDGAAVNQV (SEQ ID NO: 22) in the form of a pharmaceutically acceptable salt.
Isolated TLDGAAVNQV peptide as salt
An isolated peptide consisting of the amino acid sequence TLDGAAVNQV (SEQ ID NO: 22) in the form of a salt.
Overall, the independent claims directly cover the same isolated peptide sequence TLDGAAVNQV (SEQ ID NO: 22) in salt form, including pharmaceutically acceptable salt embodiments and related peptide compositions with optional adjuvants.
Stated Advantages
Immunotherapeutic advantages of multi-target peptide vaccines.
HLA allele coverage advantages, including HLA-A*02 and optional HLA-A*24.
Support of diagnosis/prognosis and treatment selection using peptide over-presentation and underlying gene over-expression as biomarkers.
Documented Applications
Pancreatic-cancer-focused cancer immunotherapy using tumor-associated T-cell peptide epitopes as vaccine antigens and as targets for antibodies or soluble TCRs, and for generation of TCR-engineered cells or activated T cells for killing target cells.
Biomarker use for diagnosis/prognosis and treatment selection based on peptide over-presentation and underlying gene over-expression.
Immunotherapy compositions that include adjuvants as part of peptide-based vaccine approaches.
Interested in licensing this patent?